IPO Note – Symbiotec Pharmalab Ltd (21st August 2026)

AngelOne

Company Overview

- Symbiotec Pharmalab is an R&D-driven pharmaceutical and biotechnology company with capabilities across organic chemistry, biotechnology and complex injectables. With over 30 years of experience, it has evolved from a steroidal-hormone API manufacturer into a backward-integrated platform serving both its own API portfolio and global customers through API products, CDMO services and complex injectables
- The company has a strong leadership position in corticosteroid and steroidal-hormone APIs, with FY26 global volume market shares of 38.2% and 23.8%, respectively, and is the only Indian and global company with presence across the top 10 APIs in these categories. Its portfolio comprises 44 active APIs across 10+ therapeutic areas, supported by 43 US DMFs and 23 valid CEPs, giving it a strong presence in regulated markets such as the US, Europe and Japan.
- Its manufacturing platform includes 584.67 MT of chemical synthesis capacity and 700 KL of fermentation capacity, supported by three R&D centres focused on chemistry, biotechnology and complex injectables. These specialised capabilities and regulatory approvals create high entry barriers, while rising outsourcing and supply-chain diversification away from China provide opportunities to expand in the US and European markets.
- Growth is being driven by portfolio diversification and expansion into higher-value opportunities, including classical and precision-fermentation APIs, immunosuppressants, anti-infectives, specialty ingredients and the generic version of Premarin. The company is also expanding its CDMO business through insulin, GLP-1 and classical fermentation contracts, while developing complex injectables under the US 505(b)(2) pathway.

Sector Outlook

- The global pharmaceutical market is expected to reach USD 2.2 trillion by 2030, growing at a 6.4% CAGR during 2025–30, while injectables are expected to be the fastest-growing drug-delivery segment, expanding at a 9.2% CAGR to USD 1,143.2 billion by 2030. Growth is supported by rising demand for biologics and complex drug-delivery technologies, including double-chamber systems.
- India is well placed to benefit from the “China+1” strategy, with the Indian CDMO market expected to grow at 13.5% CAGR during 202530, supported by cost advantages, a strong manufacturing ecosystem and rising global outsourcing.

Symbiotec Pharmalab Ltd

₹ 938 – 988 **Price Band**	**₹ 1,757 Cr** Issue Size
24th August – 27th August Subscription Days	**01st September 2026** Listing date

SUBSCRIBE

Particulars	IPO Details
No of Shares under IPO (Cr.)	1.7786
Post Issue MCap (Cr.)	**₹ 6,244.43**
QIB (Cr.)	0.8893
NIB (Cr.)	0.2668
Retail (Cr.)	**0.6225**

Shareholding Pattern	Pre Issue (%)	Post Issue (%)
Promoter	34.47%	31.33%
Others	65.53%	68.67%
Total	**100%**	**100%**

IPO Note – Symbiotec Pharmalab Ltd

Company Outlook

- In FY26, Symbiotec delivered steady financial growth, with revenue from operations increasing 15.65% YoY to ₹869.15 crore, while profit rose 13.55% YoY to ₹109.90 crore. The company maintained healthy profitability, with a gross margin of 63.70%, EBITDA margin of 26.59% and PAT margin of 12.60%. Its balance sheet remained moderately leveraged, with a debt-to-equity ratio of 0.33x and net debt/EBITDA of 1.64x, while liquidity stood at a current ratio of 0.92x. Capital efficiency was reflected in RoE of 11.19% and ROCE of 11.56%, with adjusted ROCE at 30.43%.

- Symbiotec Pharmalab is coming up with a ₹1,757 crore IPO, comprising a fresh issue of ₹150 crore and an OFS of ₹1,607 crore. Of the fresh issue proceeds, ₹112.50 crore will be utilised towards prepayment/repayment of certain outstanding borrowings, while the balance ₹37.50 crore is proposed to be used for general corporate purposes.

- At the upper price band of ₹988, Symbiotec Pharmalab is valued at a post-issue P/E of 56.81x, which is fairly priced compared with peers, considering its strong leadership in specialised APIs, backward-integrated manufacturing platform, regulatory capabilities and growth opportunities across CDMO and complex injectables. Given its differentiated capabilities and favourable sector outlook, we recommend a SUBSCRIBE to the issue.

Key Risks

- Symbiotec derives 96.07%, 99.10%, and 100.00% of revenue from APIs in FY26, FY25, and FY24, respectively, with its top five APIs contributing 62.27% of FY26 revenue. This concentration exposes the company to demand, pricing, regulatory, and manufacturing risks.

Particulars	FY24	FY25	FY26
Revenue (Rs. Cr)	716.25	751.55	869.15
Revenue Growth %		*4.93%*	*15.65%*
EBITDA (Rs. Cr)	177.04	206.11	231.97
EBITDA Growth %		*16.42%*	*12.55%*
EBITDA Margin %	24.48%	27.26%	26.59%
PAT (Rs. Cr)	100.06	96.79	109.90
ROCE (%)	14.03%	11.80%	11.56%

Metric FY26	Symbiotec Pharmalab	Concord Biotech	Divi's Laboratories	Cohance Lifesciences	Laurus Labs
Revenue (cr)	869	1,055	10,560	2,269	6,813
EBITDA Margin (%)	26.59%	34.80%	35.98%	19.00%	26.80%
PAT Margin (%)	12.60%	24.60%	23.93%	7.90%	13.00%
ROCE (%)	11.56%	17.00%	21.23%	10.80%	17.70%
RoNW (%)	9.48%	14.00%	16.50%	7.00%	16.80%
P/E (x)	56.81x	61.07x	87.80x	95.02x	109.36x

Disclaimer

SEBI (Research Analyst) Regulations, 2014 vide registration number: INH000000164

Aamar Deo Singh	Head Research
Osho Krishan	Sr. Analyst – Technical & Derivatives
Sneha Seth	Sr. Analyst – Technical & Derivatives
Sugreem Vishwakarma	Sr. Analyst – Technical & Derivatives
Abhishek Chauhan	Sr. Analyst – Technical & Derivatives
Hitesh Rathi	Analyst – Technical & Derivatives
Bhuvan Shah	Analyst – Technical & Derivatives
Vaqarjaved Khan, CFA	Sr. Analyst – Fundamental
Shruti Panday	Analyst – Fundamental
Sugesh Kollara	Analyst – Fundamental

We Vaqarjaved Khan, CFA, Sugesh Kollara and Shruti Panday Analyst, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Website: www.angelone.in

For Fundamental & Technical Queries E- mail: aolresearch@angelone.in

SUGESH SUDHAKARAN KOLLARA

Digitally signed by SUGESH SUDHAKARAN KOLLARA
Date: 2026.08.23 15:21:33 +05'30'

Disclaimer

We, Angel One Limited (hereinafter referred to as "Angel") a company duly incorporated under the provisions of the Companies Act, 1956 with its registered office at 601, 6th Floor, Ackruti Star, Central Road, MIDC, Andheri East, Mumbai – 400093, CIN: (L67120MH1996PLC101709) and duly registered as a member of National Stock Exchange of India Limited, Bombay Stock Exchange Limited, Metropolitan Stock Exchange Limited, Multi Commodity Exchange of India Ltd and National Commodity & Derivatives Exchange Ltd. Angel One limited is a company engaged in diversified financial services business including securities broking, DP services, distribution of Mutual Fund products. It is also registered as a Depository Participant with CDSL and Portfolio Manager and Investment Adviser with SEBI. It also has registration with AMFI as a Mutual Fund Distributor. Angel One Limited is a registered entity with SEBI for Research Analyst in terms of SEBI (Research Analyst) Regulations, 2014 vide registration number INH000000164 and also registered with PFRDA as PoP ,Registration No.19092018. Angel One Limited (formerly known as Angel Broking Limited) is the ultimate parent company of the Group. Angel or its associates has not been debarred/ suspended by SEBI or any other regulatory authority for accessing /dealing in securities Market.

We hereby declare that our activities were neither suspended nor we have defaulted with any stock exchange authority with whom we are registered. However, SEBI, Exchanges, Clearing Corporations and Depositories etc have conducted the routine inspection and based on their observations have issued advise/warning/show cause notices/deficiency letters/ or levied penalty or for certain deviations observed in inspections or in normal course of business, as a Stock Broker / Depository Participant.
AOL was merged with Angel Global Capital Private Limited and subsequently name of Angel Global Capital Private Limited was changed to Angel Broking Private Limited (AOL) pursuant to scheme of Amalgamation sanctioned by the Hon'ble High Court of Judicature at Bombay by Orders passed in Company Petition No 710 of 2011 and the approval granted by the Registrar of Companies. Further, name of Angel Broking Private Limited again got changed to Angel Broking Limited (AOL) pursuant to fresh certificate of incorporation issued by Registrar of Companies (ROC) dated June 28, 2018. Further name of Angel Broking name changed to Angel One Ltd pursuant to fresh certificate of incorporation issued by Registrar of Companies (ROC) dated 23-09-21.

In case of any grievances please write to: support@angelone.in, Compliance Officer Details: Name : Bineet Jha, Tel No. –08657864228, Email id - compliance@angelone.in
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

This document is solely for the personal information of the recipient, and must not be singularly used as the basis of any investment decision. Nothing in this document should be construed as investment or financial advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in the invest of the companies referred to in this document (including the merits and risks involved), and should consult their own advisors to determine the merits and risks of such an investment
This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Angel and its associates to any registration or licensing requirement within such jurisdiction. Angel or its associates or research analyst or his relative may have actual/beneficial ownership of 1% or more in the securities of the subject company at the end of the month immediately preceding the date of publication of the research report. Neither Angel or its associates nor Research Analysts or his relative has any material conflict of interest at the time of publication of research report.

Angel or its associates or research analyst or his relative may have actual/beneficial ownership of 1% or more in the securities of the subject company at the end of the month immediately preceding the date of publication of the research report. Neither Angel or its associates nor Research Analysts or his relative has any material conflict of interest at the time of publication of research report.

Angel or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction in the normal course of business. Angel or its associates did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with the research report. Neither research entity nor research analyst has been engaged in market making activity for the subject company.
Subject company(ies) may have been client during twelve months preceding the date of distribution of the research report.

Reports based on technical and derivative analysis center on studying charts of a stock's price movement, outstanding positions and trading volume, as opposed to focusing on a company's fundamentals and, as such, may not match with a report on a company's fundamentals. Investors are advised to refer the Fundamental and Technical Research Reports available on our website to evaluate the contrary view, if any.

Our research should not be considered as an advertisement or advice, professional or otherwise. The investor is requested to take into consideration all the risk factors including their financial condition, suitability to risk return profile and the like and take professional advice before investing.